share_log

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35

Benzinga ·  Jul 30 11:23  · Ratings

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $40 to $35.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment